Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 11:24 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 1,748 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cardiovascular Risks Clear all

Conditions: Cancer
Interventions: cytomegalovirus pp65-specific cytotoxic T lymphocytes, polymerase chain reaction, diagnostic laboratory biomarker analysis, flow cytometry, immunologic technique; Biological · Genetic · Other
Lead sponsor: University of Louisville; Other
Eligibility: 2 Years to 120 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Endothelial Dysfunction
Interventions: Atazanavir, Lopinavir/ritonavir, Placebo; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Chronic Phase Chronic Myeloid Leukemia
Interventions: Not listed
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 24
States / cities: Chicago, Illinois • Elk Grove Village, Illinois • Hoffman Estates, Illinois + 18 more

Conditions: Acute Brain Injury, Traumatic Brain Injury, Intracranial Hemorrhage, Hydrocephalus, Stroke, Brain Neoplasm, Hypoxia-Ischemia, Brain
Interventions: Not listed
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 2 Years to 17 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Obesity, Cardiovascular Diseases, Metabolic Disease, High-intensity Interval Training
Interventions: high-intensity interval training intervention; Other
Lead sponsor: Syracuse University; Other
Eligibility: 18 Years to 25 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Carotid Artery Disease, Carotid Artery Stenosis
Interventions: Carotid Artery Stenting; Device
Lead sponsor: W.L.Gore & Associates; Industry
Eligibility: 18 Years and older
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 2
States / cities: Honolulu, Hawaii • Wynnewood, Pennsylvania

Conditions: Childhood Cancer, Cardiomyopathy, Primary
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 22 Years and older
Enrollment: 1,303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Type 2 Diabetes, Cardiovascular Disease
Interventions: TAK-875, TAK-875 Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 3,207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 218
States / cities: Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 215 more

Conditions: Atherosclerosis
Interventions: Not listed
Lead sponsor: Ohio State University; Other
Eligibility: 40 Years and older · Female only
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Diabetes Mellitus
Interventions: Diffuse Optical Spectroscopy; Device
Lead sponsor: University of California, Irvine; Other
Eligibility: 45 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Irvine, California

Conditions: Bronchopulmonary Dysplasia (BPD), Hypertension, Pulmonary
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: Up to 30 Weeks
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2019
U.S. locations: 2
States / cities: Mountain View, California • Palo Alto, California

Conditions: Cushing's Disease
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 35 Years to 55 Years · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Sudden Cardiac Arrest
Interventions: Jewel Patch Wearable Cardioverter Defibrillator (P-WCD); Device
Lead sponsor: Element Science, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 322 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 30
States / cities: Jonesboro, Arkansas • Little Rock, Arkansas • Hartford, Connecticut + 25 more

Conditions: Left Ventricular Dysfunction, Coronary Artery Disease
Interventions: Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®, IABP Intra-aortic balloon pump; Device
Lead sponsor: Abiomed Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 1,252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 83
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 65 more

Conditions: Atrial Fibrillation, Stroke
Interventions: Chart Review; Other
Lead sponsor: MaineHealth; Other
Eligibility: Not listed
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Rockport, Maine

Conditions: Sars-CoV2, COVID
Interventions: Enoxaparin, Prophylactic/Intermediate Dose Enoxaparin; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 257 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 6
States / cities: Newark, New Jersey • Bay Shore, New York • Huntington, New York + 3 more

Conditions: Hypertension, Diabetes Mellitus, Hyperlipidemia
Interventions: telemedicine; Behavioral
Lead sponsor: Temple University; Other
Eligibility: 22 Years to 85 Years
Enrollment: 465 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 3
States / cities: Danville, Pennsylvania • Philadelphia, Pennsylvania

Conditions: Coronary Artery Disease
Interventions: 3 months of dual antiplatelet therapy (DAPT), SYNERGY Stent System; Drug · Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 2,009 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 89
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Bakersfield, California + 75 more

Conditions: Coronary Artery Bypass Graft Surgery, Myocardial Ischemia, Reperfusion Injury, Myocardial Revascularization
Interventions: (MC-1) Pyridoxal-5'-phosphate; Drug
Lead sponsor: Medicure; Industry
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Coronary Artery Disease, Atherosclerosis, Cardiovascular Inflammation
Interventions: CaRi-Heart® Analysis; Device
Lead sponsor: Corazon Medical PC; Other
Eligibility: Not listed
Enrollment: 15,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 18
States / cities: Bay City, Michigan • Berkley, Michigan • Caro, Michigan + 15 more

Conditions: Leukemia, Lymphoma, Hodgkin's Disease, Hematologic Neoplasms, Multiple Myeloma, Carcinoma, Renal Cell
Interventions: Pentostatin, Alemtuzumab, Allogeneic hematopoietic stem cell transplantation; Drug · Biological · Procedure
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 75 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 2
States / cities: Tucson, Arizona

Conditions: CAD - Coronary Artery Disease
Interventions: Heartflow Analysis; Device
Lead sponsor: HeartFlow, Inc.; Industry
Eligibility: 40 Years to 79 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Severe Aortic Stenosis, Cardiogenic Shock, Cardiogenic Shock, ECMO, Trans-catheter Aortic Valve Implantation
Interventions: Left Atrial Veno-Arterial Extracorporeal Membrane Oxygenation (LAVA-ECMO); Device
Lead sponsor: Atlantic Health System; Other
Eligibility: 18 Years to 100 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Detroit, Michigan • Morristown, New Jersey

Conditions: Multiple Myeloma, Primary Amyloidosis
Interventions: Melphalan, Stem Cell Infusion, Questionnaires, Granulocyte-colony stimulating factor (G-CSF), Apheresis; Drug · Procedure · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 60 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy

Effect of the HIV Protease Inhibitors Atazanavir and Lopinavir/Ritonavir on Cardiovascular Disease Risk Factors

Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Bedside Cranial Ultrasound for Risk-Stratified Imaging in Pediatric Acute Brain Injury

HIIT Effects on Cardiometabolic Health

The Gore SCAFFOLD Clinical Study

An Evaluation of Concordance of Smartwatch ECG and One Clinical ECG and Comparison of The Two ECGS in Terms of Predictive Risks

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Longitudinal Study in Perimenopausal Women With Risk Factors for Atherosclerosis

Vascular Reactivity in Metabolic Syndrome and Diabetic Patients Using Diffuse Optical Spectroscopy

Predictors of Pulmonary Hypertension Risk in Premature Infants With Bronchopulmonary Dysplasia

Long-term Cardiovascular Risk in Cured Cushing's Patients

The Jewel IDE Study

Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function

Echocardiographic Risk Factors of Stroke in Patients With Atrial Fibrillation

Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients

Preventing Heart Disease in Underserved Patients

EVOLVE Short DAPT Study

MEND-CABG (MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery)

CaRi-Heart Assessment of Risk and Evaluation of Inflammation in Coronary CT Angiography (CARE-CCTA)

Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation

REFINE-CAC Protocol: Risk Evaluation With AI-CPA + HCS For Patients IN Whom Calcium is confirmEd to Improve Coronary Artery Disease Care

Pre-Emptive LAVA-ECMO for Complex High-Risk TAVR

Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden